Published date: 23 December 2021
This notice was replaced on 23 December 2021
This notice does not contain the most up-to-date information about this procurement. The most recent notice is:
Opportunity (published 23 December 2021, last edited 19 January 2022)
Closed opportunity - This means that the contract is currently closed. The buying department may be considering suppliers that have already applied, or no suitable offers were made.
Contract summary
Industry
Pharmaceutical products - 33600000
Location of contract
WA7 2ES
Value of contract
£0 to £1
Procurement reference
CF-0547300D0O000000rwimUAA1
Published date
23 December 2021
Closing date
31 January 2022
Closing time
1pm
Contract start date
1 April 2022
Contract end date
31 March 2023
Contract type
Service contract
Procedure type
Open procedure (above threshold)
Any interested supplier may submit a tender in response to an opportunity notice.
This procedure can be used for procurements above the relevant contract value threshold.
Contract is suitable for SMEs?
No
Contract is suitable for VCSEs?
No
Description
This Tender is solely for the work involved to apply for and implement a major (type II) MHRA Marketing Authorisation variation to add a new clinical indication for anastrozole. The successful Bidder will be responsible for ensuring that all relevant MHRA conditions and documentation for the Marketing Authorisation variation are met and submitted within the time limits agreed with the Authority. In return the Authority will fund actual and reasonably incurred costs associated with obtaining this licence variation only.
Full details can be found on the Atamis portal: https://health-family.force.com/s/Welcome
Closing date for submissions is 31st January 2022 at 13:00
About the buyer
Contact name
Liz Fleetwood
Address
Rutland House
Runcorn
WA7 2ES
GB
Share this notice
All content is available under the
